Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.710
-0.016 (-2.20%)
At close: Feb 21, 2025, 4:00 PM
0.715
+0.005 (0.70%)
After-hours: Feb 21, 2025, 7:50 PM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 285 employees as of December 31, 2023. The number of employees increased by 150 or 111.11% compared to the previous year.
Employees
285
Change (1Y)
150
Growth (1Y)
111.11%
Revenue / Employee
$18,347
Profits / Employee
-$759,274
Market Cap
256.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
LXRX News
- 4 days ago - Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - GlobeNewsWire
- 4 weeks ago - Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - GlobeNewsWire
- 7 weeks ago - Lexicon Appoints Scott Coiante as Chief Financial Officer - GlobeNewsWire
- 2 months ago - US FDA declines to approve Lexicon Pharma's add-on diabetes drug - Reuters
- 2 months ago - Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - GlobeNewsWire
- 3 months ago - Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - GlobeNewsWire
- 3 months ago - Lexicon Pharmaceuticals to Participate in December Investor Conferences - GlobeNewsWire
- 3 months ago - Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development - Reuters